Aug 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S.

Semaglutide is the active ingredient in Wegovy® and Ozempic® and, unlike any other molecule in the GLP-1 class, has FDA-approved medicines with indications for patients with obesity (Wegovy®), type 2 ...